Immunohistochemistry showed that erdafitinib treatment decreased Ki67 positivity and increased cleaved caspase-3 positivity (Fig. 1d, e), indicating reduced tumor cell proliferation and increased apoptosis, consistent with effective tumor suppression. Here, CASP3 is linked to neoplasm.